Compare · JNJ vs UPB
JNJ vs UPB
Side-by-side comparison of Johnson & Johnson (JNJ) and Upstream Bio Inc. (UPB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and UPB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $611.90B, about 3266.6x UPB ($187.3M).
- Over the past year, JNJ is up 31.9% and UPB is down 84.9% - JNJ leads by 116.8 points.
- JNJ has hit the wire 16 times in the past 4 weeks while UPB has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 10 for UPB).
- Company
- Johnson & Johnson
- Upstream Bio Inc.
- Price
- $253.31-0.24%
- $3.35-1.61%
- Market cap
- $611.90B
- $187.3M
- 1M return
- -5.23%
- -37.17%
- 1Y return
- +31.87%
- -84.89%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 10
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
Latest UPB
- General Counsel Ambrose Allison sold $2,663 worth of shares (485 units at $5.49), decreasing direct ownership by 3% to 15,563 units (SEC Form 4) to satisfy withholding tax
- CFO and COO Gray Michael sold $4,683 worth of shares (853 units at $5.49), decreasing direct ownership by 3% to 27,942 units (SEC Form 4) to satisfy withholding obligation
- Chief Medical Officer Deykin Aaron sold $4,914 worth of shares (895 units at $5.49), decreasing direct ownership by 3% to 32,302 units (SEC Form 4) (for withholding tax)
- Chief Business Officer Houghton Adam sold $3,843 worth of shares (700 units at $5.49), decreasing direct ownership by 3% to 22,901 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Sutherland Everett Rand sold $11,502 worth of shares (2,095 units at $5.49), decreasing direct ownership by 3% to 68,717 units (SEC Form 4) (withholding obligation)
- Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
- Upstream Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
- Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.
- SEC Form 10-Q filed by Upstream Bio Inc.